Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.77 is 58% above its 5-year average of -1.86, near the high end of its 5-year range (-4.77–0.00).
38.40% above its 12-month average of -1.25.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.23.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T14:06:11.134Z. Historical observations retain their original dates. Historical series through 2019-04-01.
EARNINGS PER SHARE (EPS)
-0.77
EARNINGS PER SHARE (EPS) AVG TTM
-1.25
EARNINGS PER SHARE (EPS) AVG 3Y
-1.82
EARNINGS PER SHARE (EPS) AVG 5Y
-1.86
EARNINGS PER SHARE (EPS) AVG 10Y
-10.45
EARNINGS PER SHARE (EPS) AVG 15Y
-16.17
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+38.40%
CURRENT VS 3Y AVG
+57.65%
CURRENT VS 5Y AVG
+58.50%
CURRENT VS 10Y AVG
+92.63%
CURRENT VS 15Y AVG
+95.24%
CURRENT VS 20Y AVG
N/A
Cocrystal Pharma, Inc.
Market Cap
$15.44M
Earnings Per Share (EPS)
-0.77
TTM Avg
-1.25
3Y Avg
-1.82
5Y Avg
-1.86
Market Cap
$15.39M
Earnings Per Share (EPS)
-2.46
TTM Avg
-7.80
3Y Avg
-9.74
5Y Avg
-7.20
Market Cap
$15.18M
Earnings Per Share (EPS)
-13.07
TTM Avg
-13.67
3Y Avg
-19.10
5Y Avg
-23.67
Market Cap
$15.75M
Earnings Per Share (EPS)
-0.78
TTM Avg
-8.29
3Y Avg
-9461.74
5Y Avg
-302593.36
Market Cap
$16.43M
Earnings Per Share (EPS)
-0.76
TTM Avg
-2.06
3Y Avg
-5.59
5Y Avg
-9.29
Market Cap
$16.74M
Earnings Per Share (EPS)
-3.73
TTM Avg
-46.49
3Y Avg
-194.14
5Y Avg
-195.03
Market Cap
$14.14M
Earnings Per Share (EPS)
-2.11
TTM Avg
-3.38
3Y Avg
-4.90
5Y Avg
-6.31
Market Cap
$16.87M
Earnings Per Share (EPS)
-0.21
TTM Avg
-0.22
3Y Avg
-0.25
5Y Avg
-0.30
Market Cap
$13.91M
Earnings Per Share (EPS)
-1.87
TTM Avg
-10.75
3Y Avg
-23.11
5Y Avg
-21.98
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cocrystal Pharma, Inc. (COCP) | $15.44M | -0.77 | -1.25 | -1.82 | -1.86 |
| Pasithea Therapeutics Corp. (KTTA)vs › | $15.39M | -2.46 | -7.80 | -9.74 | -7.20 |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $15.18M | -13.07 | -13.67 | -19.10 | -23.67 |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.75M | -0.78 | -8.29 | -9461.74 | -302593.36 |
| BioCardia, Inc. (BCDA)vs › | $16.43M | -0.76 | -2.06 | -5.59 | -9.29 |
| Bionano Genomics, Inc. (BNGO)vs › | $16.74M | -3.73 | -46.49 | -194.14 | -195.03 |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $14.14M | -2.11 | -3.38 | -4.90 | -6.31 |
| Dyadic International, Inc. (DYAI)vs › | $16.87M | -0.21 | -0.22 | -0.25 | -0.30 |
| IN8bio, Inc. (INAB)vs › | $13.91M | -1.87 | -10.75 | -23.11 | -21.98 |
| Lipocine Inc. (LPCN)vs › | $17.19M | -1.87 | -0.88 | -1.76 | -2.28 |
Trailing EPS (TTM)
$-0.77
Forward EPS (Est.)
$-0.69
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.78 |
| 2024-12-31 | -1.72 |
| 2023-12-31 | 0.00 |
| 2022-12-31 | -4.77 |
| 2021-12-31 | -1.85 |
| 2020-12-31 | -2.01 |
| 2019-12-31 | -15.78 |
| 2018-12-31 | -21.01 |
| 2017-12-31 | -0.30 |
| 2016-12-31 | -38.17 |
| 2015-12-31 | -28.60 |
| 2014-12-31 | -0.29 |
| 2013-12-31 | -62.00 |
| 2012-12-31 | -45.41 |
| 2011-12-31 | -35.60 |
| 2010-12-31 | -0.39 |
| 2009-12-31 | -0.40 |
| 2008-12-31 | -0.51 |
| 2007-12-31 | -0.62 |
